Ilmarinen Mutual Pension Insurance Co Makes New $2.94 Million Investment in CVS Health Corporation $CVS

Ilmarinen Mutual Pension Insurance Co acquired a new position in shares of CVS Health Corporation (NYSE:CVS) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 37,000 shares of the pharmacy operator’s stock, valued at approximately $2,936,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of CVS Health by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after buying an additional 1,824,424 shares in the last quarter. Capital World Investors raised its stake in shares of CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after buying an additional 1,419,575 shares in the last quarter. State Street Corp raised its stake in shares of CVS Health by 0.3% during the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after buying an additional 149,701 shares in the last quarter. Capital International Investors raised its stake in shares of CVS Health by 1.1% during the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after buying an additional 302,499 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after buying an additional 760,579 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

CVS has been the subject of a number of analyst reports. UBS Group increased their target price on CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. DA Davidson increased their price target on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. HSBC increased their price target on shares of CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a report on Tuesday, May 5th. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, TD Cowen increased their price target on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.88.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 in the last three months. 0.85% of the stock is currently owned by company insiders.

CVS Health Stock Performance

NYSE:CVS opened at $90.97 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm has a 50-day moving average price of $82.07 and a two-hundred day moving average price of $79.55. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The company has a market capitalization of $116.06 billion, a P/E ratio of 40.07, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period last year, the firm posted $2.25 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could boost CVS’s pharmacy-benefit relevance and improve customer access to GLP-1 medications. CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: The company announced expanded GLP-1 coverage options, which management framed as improving affordability and access while supporting more sustainable long-term coverage. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
• Positive Sentiment: CVS Health expanded its collaboration with Salesforce to streamline call center interactions using AI, which could improve service quality and operating efficiency across its member and provider base. CVS Health to Deliver Faster, More Personalized Call Center Care for Millions of Members with Salesforce’s Agentforce Health
• Positive Sentiment: CVS Health also launched Aetna Mental Health On Demand and continued building out digital health capabilities, reinforcing its integrated care strategy. CVS Health Expands Integrated Care With Virtual Mental Health AI And GLP 1
• Neutral Sentiment: CVS received a Newsweek AI Impact Award for prescription-interpretation technology, highlighting innovation in pharmacy workflow and medication safety. CVS Health recognized for technology that improves medication safety and patient care
• Neutral Sentiment: Glenview Capital said CVS remains one of its top holdings, which supports investor confidence but does not by itself change fundamentals. Glenview Capital Keeps CVS Health (CVS) Among Top Holdings

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.